Regenerative Medicine

An AMWC 2026 award for RRS® HA Long Lasting signals a market shift. How Skin Tech Pharma Group is creating a new category beyond fillers and boosters.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

A new surgical method called SMART, developed at Delray Medical Center, uses biological scaffolds to overcome the failure of sutures in critical muscle injuries.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

A new partnership in regenerative medicine aims to capitalize on Florida's progressive laws. But does it signal a new era of healthspan or a risky medical frontier?

A Maryland firm just got funding for 'universal' stem cells. This isn't just science; it's the blueprint for off-the-shelf cures and a new era of medicine.

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.

Conexeu Sciences hits a key manufacturing milestone for its innovative wound-healing gel, but the path to FDA clearance and a crowded market remains a challenge.

BioCardia’s innovative cell therapy for heart failure receives a crucial FDA signal, potentially paving the way for a new treatment paradigm for millions.

Senté renewed its pact with a top scientist. We explore how deep scientific partnerships are becoming the key differentiator in a crowded, hype-filled market.

A new alliance between Made Scientific and Pluristyx promises to slash the time and cost of developing advanced iPSC therapies. But can it deliver on its promise?

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

A strategic deal between epiq Animal Health and Vetirus brings a cost-effective regenerative therapy to vets, promising wider access to advanced care.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.